Toulouse Purpan University Hospital
Welcome,         Profile    Billing    Logout  
 2 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pariente, Jeremie
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
NCT03435861: Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients

Completed
2
34
Europe
VX-745, neflamapimod, placebo
University Hospital, Toulouse, Fondation Plan Alzheimer
Alzheimer Disease
04/21
06/21
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
INHIB'MOV, NCT04768556: Brain Activity Associated With Inhibition of Action in Attention-deficit

Recruiting
N/A
60
Europe
EEG experimental sessions 1, EEG experimental sessions 2
University Hospital, Toulouse, Centre National de la Recherche Scientifique, France
Attention Deficit, Hyperactivity Disorder
12/24
12/24

Download Options